CGON
VENTE TOTALE: 26 165 titres (~1 961 951,40 $ US)
- Insiders
- POST LEONARD E, Mulay James
- Total bought
- —
- Total sold
- $1,961,951
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-07-29
CGON presents a classic high-risk biotech setup: a compelling clinical catalyst (85.7% CR rate, BLA filing plans, cash runway to 2029) is partially offset by severely weak fundamentals — persistent negative margins, no…
The first sentence of the analysis written for CGON on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -15.0% | -7108.3% | -22327.5% | 92.1% | 99.9% | |
| Ebit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.0% | -119.6% | |
| Ebitda Margin | -3949.3% | -7726.7% | -23818.6% | -18548.2% | -119.5% | |
| Operating Profit Margin | -4722.1% | -10067.3% | -27180.9% | -18453.4% | -121.7% | |
| Pretax Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Continuous Operations Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Net Profit Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% | |
| Bottom Line Profit Margin | -3985.0% | -7729.5% | -33234.3% | -22925.7% | -177.5% | |
| Current Ratio | 24.629 | 35.296 | 13.619 | 9.541 | 9.775 | |
| Quick Ratio | 24.579 | 35.296 | 13.619 | 9.541 | 9.775 | |
| Solvency Ratio | -4.092 | -4.109 | -3.348 | -1.570 | -0.696 | |
| Cash Ratio | 1.054 | 12.031 | 0.580 | 5.713 | 8.972 | |
| Price To Earnings Ratio | -19.962 | -20.340 | -36.441 | -56.318 | -132.750 | |
| Price To Earnings Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Price To Earnings Diluted Ratio | -19.962 | -20.340 | -36.441 | -56.318 | -132.750 | |
| Price To Earnings Diluted Growth Ratio | -0.420 | -0.532 | -0.668 | -0.415 | 0.000 | |
| Price To Book Ratio | 4.265 | 2.444 | 13.404 | 19.787 | 61.534 | |
| Price To Sales Ratio | 794.465 | 1,573.666 | 12,141.517 | 12,967.903 | 239.126 | |
| Price To Free Cash Flow Ratio | -24.227 | -22.704 | -54.223 | -83.066 | -180.123 | |
| Price To Operating Cash Flow Ratio | -24.252 | -22.771 | -54.223 | -83.105 | -181.402 | |
| Debt To Assets Ratio | 0.009 | 0.000 | 0.005 | 0.108 | 0.258 | |
| Debt To Equity Ratio | 0.009 | 0.000 | 0.006 | 0.127 | 0.376 | |
| Debt To Capital Ratio | 0.009 | 0.000 | 0.006 | 0.113 | 0.273 | |
| Long Term Debt To Capital Ratio | 0.004 | 0.000 | 0.000 | 0.050 | 0.231 | |
| Financial Leverage Ratio | 1.052 | 1.029 | 1.079 | 1.180 | 1.458 | |
| Working Capital Turnover Ratio | 0.006 | 0.002 | 0.001 | 0.002 | 0.000 | |
| Operating Cash Flow Ratio | -4.292 | -3.684 | -3.205 | -1.932 | -2.285 | |
| Operating Cash Flow Sales Ratio | -32.759 | -69.107 | -223.917 | -156.042 | -1.318 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.003 | 1.000 | 1.000 | 1.007 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | -85.395 | -3.951 | -3.647 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -35,246.000 | -27.951 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -80.279 | -3.324 | -4.639 | |
| Operating Cash Flow Coverage Ratio | -18.850 | -330.727 | -44.349 | -1.869 | -0.903 | |
| Capital Expenditure Coverage Ratio | -987.657 | -336.380 | 0.000 | -2,128.857 | -140.763 | |
| Dividend Paid And Capex Coverage Ratio | -987.657 | -336.380 | 0.000 | -2,128.857 | -140.763 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -19.957 | -17.448 | -50.826 | -67.877 | -196.994 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -15.0% | ▲7093.2% | ▲5836.7% |
| Ebit Margin | -3985.0% | ▲3744.5% | ▲6858.4% |
| Ebitda Margin | -3949.3% | ▲3777.4% | ▲6883.2% |
| Operating Profit Margin | -4722.1% | ▲5345.1% | ▲7386.9% |
| Pretax Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Continuous Operations Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Net Profit Margin | -3985.0% | ▲3744.5% | ▲6859.4% |
| Bottom Line Profit Margin | -3985.0% | ▲3744.5% | ▲9625.4% |
| Current Ratio | 24.630 | ▼-10.667 | ▲6.057 |
| Quick Ratio | 24.579 | ▼-10.717 | ▲6.017 |
| Solvency Ratio | -4.092 | ▲0.017 | ▼-1.329 |
| Cash Ratio | 1.054 | ▼-10.977 | ▼-4.616 |
| Price To Earnings Ratio | -19.962 | ▲0.379 | ▲33.201 |
| Price To Earnings Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Forward Price To Earnings Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Price To Earnings Diluted Ratio | -19.962 | ▲0.379 | ▲33.201 |
| Price To Earnings Diluted Growth Ratio | -0.420 | ▲0.112 | ▼-0.013 |
| Price To Book Ratio | 4.265 | ▲1.821 | ▼-16.022 |
| Price To Sales Ratio | 794.465 | ▼-779.201 | ▼-4748.870 |
| Price To Free Cash Flow Ratio | -24.227 | ▼-1.523 | ▲48.641 |
| Price To Operating Cash Flow Ratio | -24.252 | ▼-1.480 | ▲48.899 |
| Debt To Assets Ratio | 0.009 | ▲0.009 | ▼-0.067 |
| Debt To Equity Ratio | 0.009 | ▲0.009 | ▼-0.094 |
| Debt To Capital Ratio | 0.009 | ▲0.009 | ▼-0.071 |
| Long Term Debt To Capital Ratio | 0.004 | ▲0.004 | ▼-0.053 |
| Financial Leverage Ratio | 1.052 | ▲0.023 | ▼-0.108 |
| Working Capital Turnover Ratio | 0.005 | ▲0.003 | ▲0.003 |
| Operating Cash Flow Ratio | -4.292 | ▼-0.608 | ▼-1.212 |
| Operating Cash Flow Sales Ratio | -32.759 | ▲36.348 | ▲63.870 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.002 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲18.599 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲7054.790 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲17.649 |
| Operating Cash Flow Coverage Ratio | -18.850 | ▲311.877 | ▲60.489 |
| Capital Expenditure Coverage Ratio | -987.657 | ▼-651.276 | ▼-268.925 |
| Dividend Paid And Capex Coverage Ratio | -987.657 | ▼-651.276 | ▼-268.925 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -19.957 | ▼-2.509 | ▲50.663 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.21B | $1.79B | $2.48B | $2.48B | $2.48B | |
| Enterprise value | $3.18B | $1.54B | $2.47B | $2.40B | $2.44B | |
| EV / Sales | 788.16x | 1348.18x | 12106.05x | 12589.90x | 235.41x | |
| EV / Op. cash flow | -24.06x | -19.51x | -54.06x | -80.68x | -178.58x | |
| EV / Free cash flow | -24.04x | -19.45x | -54.06x | -80.64x | -177.32x | |
| EV / EBITDA | -19.96x | -17.45x | -50.83x | -67.88x | -196.99x | |
| Net debt / EBITDA | 0.16x | 2.92x | 0.15x | 2.04x | 3.11x | |
| Current ratio | 24.63x | 35.30x | 13.62x | 9.54x | 9.78x | |
| Income quality | 0.82x | 0.89x | 0.94x | 0.84x | 1.06x | |
| Graham net-net | $9 | $12 | $3 | $2 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 103.6% | |
| Working capital | $728.6M | $732.8M | $179.9M | $131.8M | $52.4M | |
| Invested capital | $759.1M | $733.3M | $180.4M | $132.3M | $52.6M | |
| Return on assets | -20.3% | -11.7% | -24.4% | -24.0% | -21.9% | |
| Operating ROA | -24.7% | -24.0% | -32.0% | -34.1% | 0.0% | |
| Return on tangible assets | -20.6% | -11.7% | -24.4% | -24.0% | -21.9% | |
| Return on equity | -21.4% | -12.0% | -26.3% | -28.3% | -31.9% | |
| Return on invested capital | -25.0% | -15.6% | -29.8% | -24.9% | -22.6% | |
| Return on capital employed | -25.1% | -15.6% | -30.0% | -26.6% | -23.9% | |
| Earnings yield | -5.0% | -4.9% | -2.0% | -1.4% | -0.5% | |
| Free cash flow yield | -4.1% | -4.4% | -1.8% | -1.2% | -0.6% | |
| Capex / Op. cash flow | -0.1% | -0.3% | 0.0% | -0.0% | -0.7% | |
| Capex / Depreciation | 9.3% | 731.3% | 0.0% | 93.3% | 970.0% | |
| Capex / Sales | 3.3% | 20.5% | 0.0% | 7.3% | 0.9% | |
| SG&A / Sales | 1820.0% | 2959.0% | 4853.4% | 3347.1% | 44.7% | |
| R&D / Sales | 2887.2% | 7208.3% | 22427.5% | 15198.4% | 176.9% | |
| Stock comp / Sales | 660.3% | 1001.1% | 749.0% | 353.9% | 10.7% | |
| Intangibles / Total assets | 1.4% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 62d | 250d | 165d | 579d | 0d | |
| Days payables outstanding | 449d | 29d | 26d | 23968d | 36610d | |
| Operating cycle | 185d | 250d | 165d | 579d | 0d | |
| Cash conversion cycle | -264d | 221d | 139d | -23389d | -36609d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+79.1%EV / Sales ▼-41.5%EV / EBITDA ▼-14.4%EV / Op. cash flow ▼-4.551Earnings yield ▼-0.001
Profitability
Return on equity ▼-0.094Return on assets ▼-0.087Return on invested capital ▼-0.094Return on capital employed ▼-0.094Operating ROA ▼-0.006Income quality ▼-0.072Tax burden 0.000
Efficiency
Days sales outstanding ▼-188.118Days payables outstanding ▲+419.835Operating cycle ▼-65.195Cash conversion cycle ▼-485.030Capex / Sales ▼-0.172R&D / Sales ▼-43.211
Balance-sheet strength
Current ratio ▼-10.667Net debt / EBITDA ▼-2.759Working capital ▼-4203000.000Invested capital ▲+25743000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+29.6%EV / Sales ▲+234.8%EV / EBITDA ▲+89.9%EV / Op. cash flow ▲+154.525Earnings yield ▼-0.045
Profitability
Return on equity ▲+0.105Return on assets ▲+0.015Return on invested capital ▼-0.024Return on capital employed ▼-0.012Operating ROA n/aIncome quality ▼-0.241Tax burden 0.000
Efficiency
Days sales outstanding ▲+62.088Days payables outstanding ▼-36160.692Operating cycle ▲+185.011Cash conversion cycle ▲+36345.703Capex / Sales ▲+0.024R&D / Sales ▲+27.103
Balance-sheet strength
Current ratio ▲+14.854Net debt / EBITDA ▼-2.949Working capital ▲+676207000.000Invested capital ▲+706446000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 CG Oncology: Circling Back After Huge Rally CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
- 2026-08-09 CG Oncology, Inc. $CGON Shares Bought by California State Teachers Retirement System California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON) by 23.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,499 shares of the company''s stock after purchasing an additional 9,841 shares during the
- 2026-08-06 CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
- 2026-08-06 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
- 2026-07-29 Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
- 2026-07-27 CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer
- 2026-07-13 CG Oncology Stock Gains 12% in Three Months: What''s Driving It? CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
- 2026-06-10 CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company''s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.
- 2026-06-09 CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- 2026-06-07 CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.